Related Experiment Video

Updated: Jun 7, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.6K

Metered-Dose Inhaler Versus Nebulizer Treatment for Acute Asthma Exacerbation: A Process Evaluation

Christopher Graybill1, Colleen Paramesh2, Jason Gray2

  • 1The University of Kansas School of Nursing, Kansas City, KS, USA cgraybill79@gmail.com.

Journal of Doctoral Nursing Practice
|November 13, 2024
PubMed

Insights

Metered-dose inhalers (MDIs) with spacers proved more effective than nebulizers for pediatric asthma exacerbations. This approach reduced clinic return visits and emergency department visits within 30 days.

Area of Science:

  • Pediatric Pulmonology
  • Public Health
  • Healthcare Management

Background:

  • Childhood asthma affects 6.5% of US children.
  • A Federally Qualified Health Center (FQHC) shifted from nebulized albuterol to metered-dose inhalers (MDIs) with spacers during the COVID-19 pandemic.
  • This change aimed to minimize pathogen aerosolization and reduce healthcare costs.

Purpose of the Study:

  • To evaluate the safety, efficacy, and efficiency of switching asthma exacerbation treatment protocols.
  • To compare nebulized albuterol with MDIs with spacers in pediatric patients.

Main Methods:

  • Retrospective chart review of pediatric patients with asthma exacerbations.
  • Comparison of nebulized albuterol versus MDI with spacer.
  • Measured 30-day return-to-care rates (ED or clinic), total treatments, and concurrent oral steroid use.

Main Results:

  • A statistically significant reduction in 30-day return-to-clinic visits was observed with MDIs.
  • Zero patients treated with MDI and spacer returned to the clinic within 30 days.
  • 61% of patients treated with nebulized albuterol returned within 30 days (p < .00001).

Conclusions:

  • Albuterol MDI with a spacer is more effective than nebulizers for reducing follow-up visits.
  • This MDI approach effectively reduces emergency department visits within 30 days.
  • Using MDIs in primary care for asthma exacerbations is cost-effective and reduces airborne exposure.

Keywords:
asthma exacerbationmetered-dose inhalernebulizerprimary health care

More Related Videos

Methodology for Sputum Induction and Laboratory Processing13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.5K
Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique13:10

Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique

Published on: May 15, 2013

56.7K

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: &#946;2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
234
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
359
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
353